# Trending Content OS — Daily Run
**Run date:** 2026-08-28

---

## 1. Preflight Summary

```yaml
preflight_status:
  all_sections_present: true
  missing_sections: []
  site_niche_set: true
  target_audience_set: true
  site_url_set: false
  serpapi_connected: true
  google_trends_available: true
  google_trends_tool: "serpapi_prefetch"
  active_tools: [google_trends_prefetch, google_news_radar]
  inactive_tools: [reddit_live, twitter_live, content_database]
  can_run_signal_listener: true
  notes: >
    site_url not configured — self-check skipped; competitor-list fallback (configs/competitor_list.yaml)
    used to inform SERP-gap context. Reddit/X live pulls not executed this run; social_spread scored
    as estimated (low weight in this niche's scoring_weights.yaml regardless). data/deferred_topics.yaml
    had no entries with a passed recheck_on date. Recent Coverage list (last 7 days) supplied in-prompt
    used as primary duplicate-detection input.
```

**Recurring-theme flags (3+ consecutive runs):**
- **FDA recall surge** — present 8/21, 8/22, 8/24, 8/25, 8/27, and again today (guacamole, herbal supplements, IV bags). USA Today's "Are food recalls increasing under RFK?" is itself a meta-commentary on this fatigue — retained as an *update*, not a new recall story.
- **Measles outbreak** (PA, MD) — appeared 8/25–8/26, no new headline in today's radar. Not re-surfaced; watch for next development.

---

## 2. Google News Radar Coverage Summary

144 unique headlines across 12 queries. Main clusters:

| Cluster | Disposition | Notes |
|---|---|---|
| **Health policy / institutional funding & PR** (state rural-health grants, NASA moon-base RFI, hospital donations, FBI raid on behavioral health facility, Sword Health–Headspace M&A, [California Social Health Council](https://www.gov.ca.gov/2026/08/27/first-partner-siebel-newsom-launches-californias-first-social-health-council-to-strengthen-community-connection/)) | **Rejected** | Local/gov PR, business M&A, or legal — no national audience health-science angle |
| **Wellness lifestyle/industry** (Oura Ring 5 review, wellness-stacking habits, campus wellness centers, [AMA on wellness-app regulation](https://www.ama-assn.org/practice-management/digital-health/it-s-time-rethink-how-wellness-apps-devices-are-regulated), [Topol/Substack wellness-industrial-complex critique](https://erictopol.substack.com/p/deborah-cohen-the-wellness-industrial)) | **Rejected — duplicate/existing** | AMA wellness-app piece and epidemiologist wellness critique both materially covered 8/26–8/27 |
| **Medical study / research** ([NMSU/UNLV GLP-1 psychiatric-safety study](https://newsroom.nmsu.edu/news/nmsu--unlv-study--glp-1s-do-not-cause-major-psychiatric-harm/s/eee6d3f8-66f0-4974-8cd9-84e547134d7d), [Cytokinetics ACACIA-HCM/NEJM](https://ir.cytokinetics.com/press-releases/press-release-details/2026/Cytokinetics-Announces-Positive-Results-from-ACACIA-HCM-Presented-in-Hot-Line-Session-at-the-European-Society-of-Cardiology-ESC-Congress-2026-and-Published-in-The-New-England-Journal-of-Medicine/default.aspx), [Zepbound cost study](https://www.prnewswire.com/news-releases/zepbound-linked-to-lower-healthcare-costs-in-adults-over-age-55-with-obesity-according-to-a-real-world-study-302859960.html)) | **Retained** | Ties to trending GLP-1/weight-loss search interest + high-tier journal sourcing |
| **Medical study — duplicate/political** ([WashU keto/Mediterranean](https://medicine.washu.edu/news/low-carb-diet-delivers-added-liver-benefits-beyond-weight-loss/), [ASCO chemo-free breast cancer](https://ascopost.com/news/august-2026/study-evaluates-chemotherapy-free-quadruplet-in-hr-positive-her2-positive-metastatic-breast-cancer/), [aging interventions](https://medicalxpress.com/news/2026-08-aging-reveals-interventions.html), [UW funding cuts](https://www.kuow.org/science/2026-08-26/uw-struggles-to-see-medical-research-through-as-trump-administration-guts-funding)) | **Rejected/Monitored** | WashU/ASCO/aging = existing (covered 8/25–8/27); UW funding-cuts framed around partisan policy — monitored, not scored, per brand-safety political-drift rule |
| **Clinical trial** (join-a-trial explainers, [NYU Langone ketamine trial](https://nyulangone.org/news/nyu-langone-health-lead-new-trial-ketamine-pain-relief), industry/business trade coverage) | **Rejected/Monitored** | "How to join a trial" pieces duplicate 8/25 coverage; NYU ketamine trial is a launch (no results yet) — deferred to monitor; AI-market/pharma-benefit trade pieces off-audience |
| **FDA recall** ([guacamole/Salmonella](https://people.com/whole-foods-guacamole-recall-gets-fda-s-highest-risk-classification-12070208), [herbal supplements](https://www.thehealthy.com/news/herbal-supplement-recalls-august-2026/), [IV bags/Baxter](https://www.ktalnews.com/health/baxter-sodium-chloride-recall/), [USA Today recall-surge/RFK data](https://www.usatoday.com/story/news/health/2026/08/28/food-recalls-under-rfk-jr-data/91494801007/)) | **Retained (new + update)** | Three genuinely new recalls not in prior 7-day coverage; blueberries/eye-drops/dog-food/levothyroxine/sprouts/cyclospora all reject as existing |
| **Trending Now — infectious disease** ([brain-eating amoeba, NC teen — WRAL](https://www.wral.com), grounded real-time Trends spike) | **Retained (update)** | New case/location vs. general topic covered 8/23 |

---

## 3. Signal Summary

```yaml
signal_summary:
  run_started_at: "2026-08-28T00:00:00Z"
  run_completed_at: "2026-08-28T00:00:00Z"
  total_signals_reviewed: 153   # 144 Google News Radar + 9 Google Trends terms
  total_signals_retained: 8
  total_rejected: 145
  google_trends_available: true
  search_velocity_source: "google_trends"
  rejection_breakdown:
    off_category: 58
    brand_safety: 4
    duplicate: 62
    weak_signal: 12
    unverified_claim: 2
    other: 7
  highest_priority_topic: "Brain-eating amoeba case, North Carolina teen"
  strongest_signal_source: "Google Trends Trending Now (grounded) + WRAL"
  tools_unavailable: [reddit_live, twitter_live, content_database]
  notes: >
    Recall cluster remains the dominant recurring theme (6th consecutive appearance);
    USA Today's RFK/recall-data piece is retained specifically because it addresses that
    fatigue with new data, not just another individual product recall. GLP-1/weight-loss
    cluster (NMSU-UNLV psychiatric study + Zepbound cost study) aligns with Google Trends
    "weight loss" rising queries (tirzepatide/medvi). Dolly Parton health-rumor spike
    (top Google Trends rising query) rejected outright — celebrity wellness, excluded category.
```

---

## 4. Skill 02b — Health Claim Verification Gate Routing Summary

| Candidate | Risk type | Primary source status | Gate result | Confidence cap |
|---|---|---|---|---|
| Whole Foods guacamole recall | recall | Single secondary (People.com) citing FDA classification; FDA.gov notice not directly retrieved | **Pass** (breaking-recall exception applied loosely — recommend direct FDA.gov verification) | Medium |
| Baxter IV bags recall | recall | Single local source (KTAL) reporting FDA-attributed action; no direct FDA/Baxter notice retrieved | **Pass** | Medium |
| Herbal supplements recall (12 products) | recall | Single source (The Healthy) citing FDA | **Pass** | Medium |
| Cytokinetics ACACIA-HCM (aficamten) | clinical_trial / drug_or_treatment_claim | NEJM publication + ESC Congress presentation + company statement — traceable, named trial | **Pass** | None (High) |
| NMSU/UNLV GLP-1 psychiatric-safety study | study_or_research / drug_or_treatment_claim | University newsroom press release describing peer-reviewed finding | **Pass** | None (institutional primary) |
| Zepbound healthcare-cost study | study_or_research / drug_or_treatment_claim | Manufacturer-sponsored real-world study (Lilly via PR Newswire), 2nd trade outlet reprints same release | **Pass**, note association≠causation | Medium |

No candidate rejected or Monitor-routed at 02b this run; all six proceed with confidence caps noted above carried into Skill 04 scoring.

---

## 5. Final Editorial Priority Board

| Priority | Topic | Publish Timing | Trend | Opportunity | Discover | Urgency | Confidence |
|---|---|---|---|---|---|---|---|
| **P1** | Brain-eating amoeba — NC teen case | immediate | 78 | 62 | 4 | now | high |
| **P1** | Baxter IV bags recall (fiberglass) | immediate | 66 | 72 | 4 | now | medium |
| **P2** | Whole Foods guacamole recall (Salmonella) | short_term | 64 | 68 | 4 | now | medium |
| **P2** | Cytokinetics ACACIA-HCM (NEJM/ESC) | short_term | 60 | 70 | 4 | today | high |
| **P2** | NMSU/UNLV GLP-1 psychiatric-safety study | short_term | 68 | 72 | 4 | today | medium |
| **P2** | Herbal supplements recall (12 products) | short_term | 58 | 65 | 4 | today | medium |
| **P3** | Zepbound real-world healthcare-cost study | scheduled | 55 | 58 | 3 | this_week | medium |
| **P3** | "Are food recalls increasing under RFK?" (data update) | scheduled | 54 | 60 | 3 | this_week | medium |

```yaml
summary:
  total_topics: 8
  high_priority_count: 2
  immediate_actions: "Brain-eating amoeba NC case and Baxter IV bag recall both require same-day publishing turnaround."
```

---

## 6. Editorial Briefs (Retained Candidates)

### P1 — Brain-eating amoeba: North Carolina teen case
```yaml
priority_level: P1
publish_timing: immediate
topic: "Rare Naegleria fowleri (brain-eating amoeba) infection confirmed in NC teen after swimming"
primary_entity: "Naegleria fowleri — North Carolina case"
signal_type: breaking_news
allowed_category: "infectious disease"
trend_strength_score: 78
opportunity_score: 62
discover_score: 4
urgency: now
confidence: high
content_status: update
source_count: 2
recommended_angle: "Explain actual infection risk/rarity + concrete water-exposure safety guidance, cutting through search-driven fear spike"
why_now: "Confirmed real-time Google Trends breakout ('brain eating amoeba north carolina') directly grounded by WRAL reporting on a new NC teen case — distinct new case/location vs. the general topic covered 8/23"
primary_headline: "Brain-Eating Amoeba Case in North Carolina: What Swimmers Actually Need to Know"
next_steps: "Assign immediately; pull CDC Naegleria fowleri risk data for context; avoid sensationalized framing"
notes: "No overstatement risk — signal_type doesn't trigger 02b. Opportunity capped moderate since national outlets will cover fast; win via clarity/context, not speed."
```

### P1 — Baxter IV bags recall (fiberglass contamination)
```yaml
priority_level: P1
publish_timing: immediate
topic: "FDA recall of Baxter IV saline bags over possible fiberglass contamination"
primary_entity: "Baxter International — sodium chloride IV bags"
signal_type: recall
allowed_category: "FDA and CDC regulatory updates"
trend_strength_score: 66
opportunity_score: 72
discover_score: 4
urgency: now
confidence: medium
content_status: new
source_count: 1
recommended_angle: "Patient-facing explainer: what this recall means for hospital patients, how to check if you/a loved one is affected"
why_now: "New FDA-attributed recall not present in prior 7-day coverage; involves hospital IV supply chain, higher stakes than typical food recall"
primary_headline: "Baxter Recalls IV Bags Nationwide Over Fiberglass Contamination Risk — What Patients Should Know"
next_steps: "Verify direct FDA.gov/Baxter recall notice before publishing (single-source flag); confirm lot numbers and distribution scope"
notes: "⚠️ Only one media source (KTAL) found — confidence capped Medium per 02b; do not publish without direct primary verification."
```

### P2 — Whole Foods guacamole recall
```yaml
priority_level: P2
publish_timing: short_term
topic: "FDA classifies Whole Foods guacamole recall as highest risk over Salmonella-linked jalapeño supplier"
primary_entity: "Whole Foods guacamole recall — Salmonella"
signal_type: recall
allowed_category: "FDA and CDC regulatory updates"
trend_strength_score: 64
opportunity_score: 68
discover_score: 4
urgency: now
confidence: medium
content_status: new
source_count: 2
recommended_angle: "Use FDA's Class I classification system as the hook — explain what 'highest risk' actually means for consumers, tie into RFK recall-surge conversation"
why_now: "New product/supplier not covered in prior recall stories this week; distinct from lettuce/sprout cyclospora and dog food recalls already covered"
primary_headline: "FDA Gives Whole Foods Guacamole Recall Its Highest Risk Rating — Here's What That Means"
next_steps: "Verify FDA.gov recall notice directly; check for lot codes/state distribution before publishing"
notes: "⚠️ Confidence capped Medium — single named secondary source (People.com) citing FDA action."
```

### P2 — Cytokinetics ACACIA-HCM (NEJM/ESC)
```yaml
priority_level: P2
publish_timing: short_term
topic: "Aficamten shows positive results for hypertrophic cardiomyopathy in ACACIA-HCM trial, published in NEJM"
primary_entity: "Cytokinetics — aficamten / ACACIA-HCM trial"
signal_type: clinical_trial
allowed_category: "chronic disease management"
trend_strength_score: 60
opportunity_score: 70
discover_score: 4
urgency: today
confidence: high
content_status: new
source_count: 3
recommended_angle: "Translate NEJM/ESC trial data into plain-language patient explainer: what this means for hypertrophic cardiomyopathy treatment, without over-claiming approval status"
why_now: "Simultaneous NEJM publication + ESC Congress presentation — gold-standard sourcing convergence, thin consumer-facing coverage so far"
primary_headline: "New Heart Drug Trial Shows Promise for Hypertrophic Cardiomyopathy — What the NEJM Study Found"
next_steps: "Pull NEJM abstract directly; clarify trial phase and current FDA approval status before publishing"
notes: "⚠️ Company-issued press release — flag industry funding; distinguish trial results from any regulatory approval."
```

### P2 — NMSU/UNLV GLP-1 psychiatric-safety study
```yaml
priority_level: P2
publish_timing: short_term
topic: "New study finds GLP-1 drugs do not cause major psychiatric harm"
primary_entity: "GLP-1 receptor agonists — psychiatric safety"
signal_type: study_or_research
allowed_category: "chronic disease management"
trend_strength_score: 68
opportunity_score: 72
discover_score: 4
urgency: today
confidence: medium
content_status: new
source_count: 1
recommended_angle: "Address a real audience anxiety (GLP-1 + mental health safety) directly, using the study to calm/clarify rather than alarm — ties to trending weight-loss/tirzepatide search interest"
why_now: "New NMSU/UNLV finding lands amid heavy consumer GLP-1 usage and rising 'tirzepatide'/'medvi' search interest in Google Trends weight-loss category"
primary_headline: "Do GLP-1 Drugs Like Ozempic Cause Mental Health Problems? New Study Says No"
next_steps: "Trace to underlying peer-reviewed publication; confirm study design (observational vs. controlled) before finalizing framing"
notes: "⚠️ Single institutional press release — verify study design and avoid overstating 'no harm' as absolute."
```

### P2 — Herbal supplements recall (12 products)
```yaml
priority_level: P2
publish_timing: short_term
topic: "FDA recalls 12 herbal supplements"
primary_entity: "FDA herbal supplement recalls, August 2026"
signal_type: recall
allowed_category: "FDA and CDC regulatory updates"
trend_strength_score: 58
opportunity_score: 65
discover_score: 4
urgency: today
confidence: medium
content_status: new
source_count: 1
recommended_angle: "Consumer checklist: which 12 products, what contamination/potency issue, how to check your own supplement cabinet"
why_now: "New, distinct recall list not covered in prior 7-day recall coverage (levothyroxine, dog food, eye drops)"
primary_headline: "FDA Recalls These 12 Herbal Supplements — Full List and What to Do"
next_steps: "Verify full product list against FDA enforcement report before publishing"
notes: "⚠️ Single source (The Healthy) — confirm against FDA.gov before publishing."
```

### P3 — Zepbound real-world healthcare-cost study
```yaml
priority_level: P3
publish_timing: scheduled
topic: "Zepbound linked to lower healthcare costs in older adults with obesity, real-world study finds"
primary_entity: "Zepbound (tirzepatide) — healthcare cost study"
signal_type: study_or_research
allowed_category: "chronic disease management"
trend_strength_score: 55
opportunity_score: 58
discover_score: 3
urgency: this_week
confidence: medium
content_status: new
source_count: 2
recommended_angle: "Evaluative angle: what an industry-funded cost study can and can't tell patients about GLP-1 value"
why_now: "Adds an economics angle to the ongoing GLP-1/weight-loss news cycle"
primary_headline: "Does Zepbound Actually Save Money on Healthcare? What a New Study Found"
next_steps: "Flag industry sponsorship prominently; seek independent health-economics expert comment"
notes: "⚠️ Eli Lilly-sponsored real-world study — association, not causation; needs independent framing."
```

### P3 — "Are food recalls increasing under RFK?" (update)
```yaml
priority_level: P3
publish_timing: scheduled
topic: "Data analysis: are FDA food recalls actually increasing under RFK Jr.'s HHS?"
primary_entity: "FDA food recall trends — RFK Jr./HHS oversight"
signal_type: data_release
allowed_category: "FDA and CDC regulatory updates"
trend_strength_score: 54
opportunity_score: 60
discover_score: 3
urgency: this_week
confidence: medium
content_status: update
source_count: 1
recommended_angle: "Data-driven follow-up to our 8/24 recall-surge explainer — is it more recalls, or more detection/reporting?"
why_now: "New development since 8/24 explainer: specific data analysis tied to current HHS leadership, directly addressing audience 'why so many recalls lately' fatigue"
primary_headline: "Are Food Recalls Really Increasing? What the Data Shows"
next_steps: "Request underlying FDA recall-count dataset cited by USA Today; avoid partisan framing per brand-safety rules"
notes: "Handle RFK/HHS framing carefully — keep data-focused, not partisan opinion, per excluded 'pure political healthcare opinion' category."
```

---

## 7. Rejected Topics Log (representative — grouped)

| Topic cluster | Reason |
|---|---|
| Dolly Parton health rumors/death (top Trends rising query) | off_category — celebrity wellness, excluded |
| WashU keto/Mediterranean, Scientific American keto piece | duplicate — covered 8/27 |
| ASCO chemo-free breast cancer quadruplet | duplicate — same narrative as Mount Sinai story, 8/25 |
| Aging interventions (Medical Xpress) | duplicate — overlaps Nature Medicine aging study, 8/27 |
| Frozen blueberries, eye drops, Fromm dog food, levothyroxine, E. coli/Salmonella sprouts, Cyclospora explainer | duplicate — all covered 8/21–8/27 (dog food additionally excluded: pet health) |
| "How to join a clinical trial" (CNN, Cancer Health) | duplicate — covered 8/25 |
| NYU Langone ketamine trial | weak_signal — trial launch stage, no results; deferred to monitor |
| UW research-funding cuts (Trump admin) | brand_safety — partisan policy framing risk; monitored, not scored |
| Meta/teen mental health settlement (NYT) | other — thin unique health-science angle, NYT already owns definitive coverage |
| PBS Maui wildfire health (3-year anniversary) | weak_signal — saturated anniversary piece, low freshness |
| FBI raid on Detroit behavioral health facility | off_category — legal/investigative, not health-science |
| Sword Health–Headspace acquisition | off_category — pure business M&A |
| State rural-health funding grants (AR, AL), NASA moon-base RFI, Raiders hospital donation | off_category — local/gov PR, not national audience relevance |
| Campus/institutional wellness news (Pratt, CSUF, Miami U, UTHSC, Army, VA garden) | off_category — local institutional PR |
| Oura Ring 5 review, wellness-stacking article | off_category/duplicate — product review or covered wellness-critique theme |
| AMA wellness-app regulation piece | duplicate — covered 8/27 |
| UCLA healthcare-access barriers study, Nature AI-in-medicine review | weak_signal — legitimate but deferred for capacity; monitor for next run |
| Industry/trade coverage (MarketsandMarkets, Pharmaceutical Commerce, Clinical Leader, Tufts Now, Allegheny press release, Wolters Kluwer product page) | off_category — B2B/vendor content, not consumer audience |
| UnityPoint Health labor lawsuit | off_category — business/legal |
| USDA Screwworm.gov resource page | off_category — agricultural/animal health, not zoonotic news event |

Full 145-item rejection tally by reason is in `signal_summary.rejection_breakdown` above.

---

## 8. Integrity Flags Callout

⚠️ Whole Foods guacamole recall — FDA notice not directly retrieved; single secondary source; verify FDA.gov before publishing.
⚠️ Baxter IV bag recall — single local-news source; verify FDA/Baxter notice directly before publishing.
⚠️ Herbal supplement recall — single source; confirm full product list against FDA enforcement report.
⚠️ Cytokinetics ACACIA-HCM — company-issued press release; distinguish trial results from any regulatory approval status; note industry funding.
⚠️ NMSU/UNLV GLP-1 study — confirm observational vs. controlled design; do not overstate "no harm" as absolute.
⚠️ Zepbound cost study — Eli Lilly–sponsored; association ≠ causation; needs independent expert framing.

---

## 9. Run Notes

- No entries in `data/deferred_topics.yaml` had a passed `recheck_on` date this run.
- FDA recall coverage is now a 6-consecutive-run recurring theme; USA Today's RFK/data-driven update was deliberately prioritized over a 4th standalone product recall to address reader fatigue directly.
- GLP-1/weight-loss cluster (psychiatric-safety study + Zepbound cost study) aligns with live Google Trends rising queries ("medvi," "tirzepatide") — good convergence signal.
- Self-check skipped (`site_url` unset); competitor-list fallback used for SERP-gap context on all retained candidates.
- Reddit/X live pulls not executed this run — social_spread component estimated from news volume only; low-weight impact given this niche's scoring_weights.yaml (0.15).
- Three candidates (Baxter IV bags, guacamole, herbal supplements) carry Medium confidence caps solely due to single-source recall reporting — recommend editorial team verify each against FDA.gov directly before publish, per the notes on each brief.
- UW research-funding story and NYU ketamine trial held back from the board (monitor status) rather than scored, given political-framing risk and pre-results trial stage respectively — revisit if new developments emerge.